What is the prevalence of Nonketotic Hyperglycinemia?

Nonketotic Hyperglycinemia (NKH) is a rare genetic disorder characterized by the accumulation of glycine, an amino acid, in the body. It is caused by a deficiency of the enzyme glycine cleavage system, which is responsible for breaking down glycine. The prevalence of NKH is estimated to be around 1 in 60,000 to 1 in 250,000 live births worldwide. Although it is considered a rare disorder, the exact prevalence may vary across different populations and regions.

NKH typically presents in the neonatal period, with symptoms including lethargy, seizures, hypotonia, and breathing difficulties. The severity of the condition can vary, ranging from mild to severe forms. Severe cases often result in significant developmental delays, intellectual disabilities, and neurological problems.

Early diagnosis and intervention are crucial for managing NKH. Treatment mainly focuses on reducing glycine levels through a strict low-protein diet, medications, and supportive care. However, the prognosis remains poor for many affected individuals, and the long-term outcomes can be challenging.

Further research and awareness are necessary to better understand the prevalence and impact of Nonketotic Hyperglycinemia, as well as to develop more effective treatments for this rare genetic disorder.